In hematologic malignancies, alterations in AGO1 function could potentially contribute to the dysregulation of hematopoietic gene expression by influencing chromatin architecture and transcriptional reprogramming, thus contributing to leukemic transformation [21]. This evidence concerns the gene AGO1 and hematologic disorder.